The urea decomposition product cyanate promotes endothelial dysfunction

Kidney International

Volumn 86, Issue 5, 2014, Pages 923-931

  El Gamal, Dalia ^a   Rao, Shailaja P ^a   Holzer, Michael ^a   Hallström, Seth ^a   Haybaeck, Johannes ^a   Gauster, Martin ^a   Wadsack, Christian ^a   Kozina, Andrijana ^a   Frank, Saša ^a   Schicho, Rudolf ^a   Schuligoi, Rufina ^a   Heinemann, Akos ^a   Marsche, Gunther ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

cyanate; endothelial nitric oxide synthase; plasminogen activator inhibitor 1; renal disease; tissue factor

Indexed keywords

ACETYLCHOLINE; CYANIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPITOPE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; THROMBOPLASTIN; UREA; CITRULLINE; CYANIC ACID DERIVATIVE; HOMOCITRULLINE; MESSENGER RNA; NOS3 PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CARBAMOYLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VASCULAR RING; VASODILATATION; ANALOGS AND DERIVATIVES; ANIMAL; AORTA; C57BL MOUSE; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN PROCESSING; TIME; VASCULAR ENDOTHELIUM;

ADMINISTRATION, INHALATION; ANIMALS; AORTA; CELLS, CULTURED; CITRULLINE; CYANATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MALE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, MESSENGER; THROMBOPLASTIN; TIME FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 84908571183     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.218     Document Type: Article

References (36)

1. Lindner A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701
2. Stenvinkel P. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. J Ren Nutr 2003; 13: 144-148
3. Dobre M, Meyer TW, Hostetter TH. Searching for uremic toxins. Clin J Am Soc Nephrol 2013; 8: 322-327
4. Kraus LM, Kraus AP Jr. The search for the uremic toxin: the case for carbamoylation of amino acids and proteins. Wien Klin Wochenschr 1998; 110: 521-530
5. Lameire N, Vanholder R, De Smet R. Uremic toxins and peritoneal dialysis. Kidney Int Suppl 2001; 78: S292-S297
6. Evenepoel P, Meijers BK, Bammens BR, et al. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009; 76(Suppl 114): S12-S19
7. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13: 1176-1184
8. El-Gamal D, Holzer M, Gauster M, et al. Cyanate is a novel inducer of endothelial icam-1 expression. Antioxid Redox Signal 2012; 16: 129-137
9. Holzer M, Zangger K, El-Gamal D, et al. Myeloperoxidase-Derived Chlorinating Species Induce Protein Carbamylation Through Decomposition of Thiocyanate and Urea: Novel Pathways Generating Dysfunctional High-Density Lipoprotein. Antioxid Redox Signal 2012; 17: 1043-1052
10. Koeth RA, Kalantar-Zadeh K, Wang Z, et al. Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol 2013; 24: 853-861
11. Berg AH, Drechsler C, Wenger J, et al. Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 2013; 5: 175ra29
12. Bell JD, Lee JA, Lee HA, et al. Nuclear-magnetic-resonance studies of blood-plasma and urine from subjects with chronic-renal-failureidentification of trimethylamine-n-oxide. Biochim Biophys Acta 1991; 1096: 101-107
13. Blackmore DJ, Elder WJ, Bowden CH. Urea distribution in renal failure. J Clin Pathol 1963; 16: 235-243
14. Dirnhuber P, Schutz F. The isomeric transformation of urea into ammonium cyanate in aqueous solutions. Biochem J 1948; 42: 628-632
15. Marsche G, Saemann MD, Heinemann A, et al. Inflammation alters HDL composition and function: Implications for HDL-raising therapies. Pharmacol Ther 2013; 137: 341-351
16. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731
17. Westrick RJ, Bodary PF, Xu Z, et al. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 2001; 103: 3044-3046
18. Ploplis VA. Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease. Curr Drug Targets 2011; 12: 1782-1789
19. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943
20. Vanholder RC, Glorieux GL. An overview of uremic toxicity. Hemodial Int 2003; 7: 156-161
21. Holzer M, Gauster M, Pfeifer T, et al. Protein carbamylation renders highdensity lipoprotein dysfunctional. Antioxid Redox Signal 2011; 14: 2337-2346
22. Hogas SM, Voroneanu L, Serban DN, et al. Methods and potential biomarkers for the evaluation of endothelial dysfunction in chronic kidney disease: a critical approach. J Am Soc Hypertens 2010; 4: 116-127
23. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-152
24. Landray MJ, Wheeler DC, Lip GY, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244-253
25. Thambyrajah J, Landray MJ, McGlynn FJ, et al. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000; 83: 205-209
26. Shu L, Park JL, Byun J, et al. Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J Am Soc Nephrol 2009; 20: 1975-1985
27. Feletou M, Kohler R, Vanhoutte PM. Nitric oxide: orchestrator of endothelium-dependent responses. Ann Med 2011; 44: 694-716
28. Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vascul Pharmacol 2006; 45: 268-276
29. Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997; 75: 125-139
30. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87-92
31. Sharma S, Farrington K, Kozarski R, et al. Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. Eur Heart J 2013; 34: 354-363
32. Andelid K, Bake B, Rak S, et al. Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms. Respir Med 2007; 101: 888-895
33. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-1295
34. de Sousa MG, Yugar-Toledo JC, Rubira M, et al. Ascorbic acid improves impaired venous and arterial endothelium-dependent dilation in smokers. Acta Pharmacol Sin 2005; 26: 447-452
35. Cacicedo JM, Gauthier MS, Lebrasseur NK, et al. Acute exercise activates AMPK and eNOS in the mouse aorta. Am J Physiol Heart Circ Physiol 2011; 301: H1255-H1265
36. Damm M, Holzer M, Radspieler G, et al. Microwave-Assisted highthroughput acid hydrolysis in silicon carbide microtiter platforms-A rapid and low volume sample preparation technique for total amino acid analysis in proteins and peptides. J Chromatogr A 2010; 1217: 7826-7832